A Fermented Chili Soup From Guizhou May Help the Liver Stop Overproducing Sugar

A traditional fermented dish from the Qiandongnan region of Guizhou Province may do something that pharmaceutical researchers have spent decades trying to replicate: quietly tell the liver to stop flooding the bloodstream with glucose. A new study published in Food Science and Nutrition found that Miao Sour Soup (MSS) activated the PI3K/Akt/Foxo1 signaling pathway in high-fat diet rats, suppressing two key enzymes that drive excessive hepatic gluconeogenesis. This is early, preliminary research, and the leap from rat livers to human metabolic medicine is long. But the mechanistic specificity of the findings makes it worth unpacking.

Miao Sour Soup's Effect on Liver Glucose Output

Gluconeogenesis is the liver's process of manufacturing new glucose from non-sugar precursors, a function that is essential during fasting but becomes destructive when chronically overactive. In type 2 diabetes and obesity, this process runs too hot, contributing to persistently elevated blood sugar even when a person has eaten. Hepatic gluconeogenesis dysregulation is a well-documented driver of hyperglycemia in metabolic disease, and correcting it is a central target of drugs like metformin.

In the Guizhou study, rats fed a high-fat diet for 12 weeks developed the expected metabolic disruptions: elevated blood lipids, high blood glucose, and substantial fat accumulation in the liver. When researchers introduced MSS at 8 grams per kilogram of body weight per day, blood lipid and glucose levels dropped significantly. More specifically, Western blot analysis showed decreased expression of two proteins central to gluconeogenesis: PEPCK (phosphoenolpyruvate carboxykinase) and G6PC (glucose-6-phosphatase). Both enzymes are direct transcriptional targets of Foxo1, a transcription factor that, when active, keeps the gluconeogenesis program running. The data suggest MSS pushed Foxo1 out of the nucleus by activating Akt, the kinase that phosphorylates Foxo1 and suppresses its transcriptional activity on glucose production genes.

Why Chronic Liver Inflammation Is the Hidden Link

The mechanism appears to run through inflammation before it reaches the signaling pathway. Obesity-driven fat accumulation promotes chronic low-grade inflammation, and that inflammatory state interferes with insulin signaling, including the PI3K/Akt cascade that normally keeps gluconeogenesis in check. The study found that MSS decreased NF-kB expression in rat livers, indicating reduced inflammatory signaling. This matters because NF-kB activation is one route by which inflammatory cytokines blunt Akt activity. Pro-inflammatory cytokines TNF-alpha and IL-6, which prior MSS research found elevated in the intestinal mucosa of obese rats, were also reduced in the current study.

The bioactive constituents of MSS, lycopene, capsaicin, and short-chain fatty acids produced during fermentation, all carry documented anti-inflammatory properties. Lycopene has been associated with reduced diet-induced obesity and insulin resistance; capsaicin has been linked to improved glucose and lipid metabolism. Neither finding is definitive on its own, but their presence together in a fermented food raises the question of whether the combination produces effects that no single compound would.

For the roughly half a billion adults living with type 2 diabetes worldwide, better glycemic control remains an urgent challenge. Dietary interventions can meaningfully improve glycemic outcomes in people with T2DM, and identifying food-based compounds that engage specific molecular targets could eventually expand that toolkit.

How Researchers Built the Rat Model and Measured the Pathway

The team induced metabolic dysfunction by feeding Sprague-Dawley rats a high-fat diet composed of 78.8% normal feed, 10% lard, 10% egg yolk powder, 1% cholesterol, and 0.2% bile salt for 12 weeks, a composition that reliably triggers obesity, dyslipidemia, and impaired glucose tolerance. High-fat diets of this type are well-validated for inducing metabolic syndrome features in rodents, giving the model reasonable face validity for studying the downstream pathways.

Beyond standard lipid and glucose panels, the researchers ran a non-targeted metabolomics analysis on liver tissue, which pointed toward disruptions in glycolysis and gluconeogenesis pathways. Western blotting then allowed them to confirm changes at the protein level in the NF-kB and PI3K/Akt/Foxo1 cascades. The combination of untargeted metabolomics with targeted protein analysis is a reasonable two-step approach: the metabolomics flags which pathways are shifting, and the Western blots confirm whether the key regulatory proteins are moving in the expected direction.

Open Questions About MSS and Translational Scope

Several important limitations temper the findings. This is a rat study with a single MSS dose, so dose-response relationships and safety at higher or lower intakes remain unknown. The precise bioactive compound driving the PI3K/Akt/Foxo1 effect has not been isolated. MSS is a complex fermented food whose composition can vary with batch, fermentation time, and regional ingredient sourcing, which makes standardization difficult for any future clinical work. FoxO1 coordinates gene expression across multiple tissues, so any intervention targeting this pathway in humans would need careful evaluation of off-target effects.

The study also does not follow the rats long enough to determine whether the gluconeogenesis suppression translates into meaningful reductions in diabetes-related complications. Animal models, even well-constructed ones, routinely fail to replicate in human trials.

What the Guizhou Research Team Plans to Investigate Next

The authors identify Foxo1 as a priority target for follow-up, given its central role in coordinating glucose metabolism in the context of lipid disease. Prior work from the same research group showed that MSS also activates AMPKalpha and inhibits SREBP-1c and fatty acid synthase, suggesting the soup influences lipid and glucose metabolism through at least two partially separate signaling arms. Untangling which constituents drive which effects, and whether those effects are additive or redundant, is the logical next step. Human trials, if the mechanistic picture sharpens, remain a longer-horizon prospect. For now, the fermented chili soup from Guizhou joins a growing body of evidence that traditional fermented foods can carry biologically active compounds with specific, testable mechanisms.

Evidence rating

INVESTIGATIONAL — 78/100

Caveats:

• This study was conducted entirely in rats; results have not been tested in humans.
• No funding source was disclosed, so independent replication has not been confirmed.
• The study cannot establish whether the effect is driven by the fermented food as a whole or any single bioactive compound.

Rodent intervention study using a high-fat diet model. Demonstrates a mechanistic pathway (NF-κB → PI3K/Akt/Foxo1 → PEPCK/G6PC) with supporting metabolomics and Western blot data, but findings are limited to an animal model and cannot be extrapolated to humans without further study. Not yet replicated in an independent population.